Q1 also proved to be a mundane quarter for Sanofi, with the sales performance falling short of the Street’s expectations. Although it is widely known that the year will be back-end loaded, some pockets languished more than anticipated, thus putting more pressure on the second half and the annual targets. The Dupixent, Toujeo, Dengvaxia, vaccines in emerging markets, were the main disappointments during the quarter.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Mediocre quarter
Q1 also proved to be a mundane quarter for Sanofi, with the sales performance falling short of the Street’s expectations. Although it is widely known that the year will be back-end loaded, some pockets languished more than anticipated, thus putting more pressure on the second half and the annual targets. The Dupixent, Toujeo, Dengvaxia, vaccines in emerging markets, were the main disappointments during the quarter.